These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21045681)

  • 41. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study.
    Phan BA; Muñoz L; Shadzi P; Isquith D; Triller M; Brown BG; Zhao XQ
    Am J Cardiol; 2013 Feb; 111(3):352-5. PubMed ID: 23168285
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Niacin's effect on cardiovascular risk: have we finally learned our lesson?
    Nicholls SJ
    Cleve Clin J Med; 2014 May; 81(5):275-7. PubMed ID: 24789584
    [No Abstract]   [Full Text] [Related]  

  • 44. Fibrates.
    Robillard R; Fontaine C; Chinetti G; Fruchart JC; Staels B
    Handb Exp Pharmacol; 2005; (170):389-406. PubMed ID: 16596808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance.
    Linke A; Sonnabend M; Fasshauer M; Höllriegel R; Schuler G; Niebauer J; Stumvoll M; Blüher M
    Atherosclerosis; 2009 Jul; 205(1):207-13. PubMed ID: 19131065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of extended-release niacin with laropiprant in high-risk patients.
    ; Landray MJ; Haynes R; Hopewell JC; Parish S; Aung T; Tomson J; Wallendszus K; Craig M; Jiang L; Collins R; Armitage J
    N Engl J Med; 2014 Jul; 371(3):203-12. PubMed ID: 25014686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.
    Guyton JR
    Curr Opin Lipidol; 2007 Aug; 18(4):415-20. PubMed ID: 17620858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The mechanism and mitigation of niacin-induced flushing.
    Kamanna VS; Ganji SH; Kashyap ML
    Int J Clin Pract; 2009 Sep; 63(9):1369-77. PubMed ID: 19691622
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-atherosclerotic molecules targeting oxidative stress and inflammation.
    Adameova A; Xu YJ; Duhamel TA; Tappia PS; Shan L; Dhalla NS
    Curr Pharm Des; 2009; 15(27):3094-107. PubMed ID: 19754384
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens.
    Dunbar RL; Goel H
    Curr Atheroscler Rep; 2016 Feb; 18(2):11. PubMed ID: 26876225
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
    Offermanns S
    Trends Pharmacol Sci; 2006 Jul; 27(7):384-90. PubMed ID: 16766048
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
    Haynes R; Valdes-Marquez E; Hopewell JC; Chen F; Li J; Parish S; Landray MJ; Armitage J; ; ;
    Clin Ther; 2019 Sep; 41(9):1767-1777. PubMed ID: 31447131
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanism of action of niacin.
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids.
    Wu BJ; Yan L; Charlton F; Witting P; Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2010 May; 30(5):968-75. PubMed ID: 20167660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl.
    Andrews TC; Whitney EJ; Green G; Kalenian R; Personius BE
    Am J Cardiol; 1997 Oct; 80(7):831-5. PubMed ID: 9381993
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.
    Kühnast S; Louwe MC; Heemskerk MM; Pieterman EJ; van Klinken JB; van den Berg SA; Smit JW; Havekes LM; Rensen PC; van der Hoorn JW; Princen HM; Jukema JW
    PLoS One; 2013; 8(6):e66467. PubMed ID: 23840481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trial.
    Nasser Figueiredo V; Vendrame F; Colontoni BA; Quinaglia T; Roberto Matos-Souza J; Azevedo Moura F; Coelho OR; de Faria EC; Sposito AC
    Clin Ther; 2014 Jun; 36(6):961-6. PubMed ID: 24768191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Niacin, an old drug with a new twist.
    Song WL; FitzGerald GA
    J Lipid Res; 2013 Oct; 54(10):2586-94. PubMed ID: 23948546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin?
    Ledwidge MT; Ryan F; Kerins DM; O'Connell D; Cefali G; Harmon S; Jones M; Gilmer JF
    Atherosclerosis; 2012 Apr; 221(2):478-83. PubMed ID: 22326030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.